Status:
RECRUITING
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Colorectal Cancer
Ovarian Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This...
Eligibility Criteria
Inclusion
- One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney
- Above 18 years of age
- Failure of at least one chemotherapy protocol
- Clinical performance status of ECOG 0,1
- Absolute neutrophil count greater than 1000/mm3
- Serum ALT/AST less than three times the upper limit of normal
- Serum creatinine less than or equal to 1.6 mg/dl.
- Must be able to understand and sign the Informed Consent document
Exclusion
- Below 18 years of age
- Women who are pregnant
- Life expectancy of less than three months
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00722228
Start Date
July 1 2008
End Date
January 1 2027
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120